Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells

Metformin exerts direct anti-tumor effects by activating AMP-activated protein kinase (AMPK), a major sensor of cellular metabolism in cancer cells. This, in turn, inhibits pro-survival mTOR signaling. Metformin has also been shown to disrupt complex 1 of the mitochondrial electron transport chain....

Descripción completa

Detalles Bibliográficos
Autores principales: Chukkapalli, Vineela, Gordon, Leo I., Venugopal, Parameswaran, Borgia, Jeffrey A., Karmali, Reem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940409/
https://www.ncbi.nlm.nih.gov/pubmed/29765528
http://dx.doi.org/10.18632/oncotarget.24989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940409/
https://www.ncbi.nlm.nih.gov/pubmed/29765528
http://dx.doi.org/10.18632/oncotarget.24989

Ejemplares similares